Are you Dr. Peyrani?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 4 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
501 E Broadway
Suite 120
Louisville, KY 40202Phone+1 502-852-3905
Summary
- Dr. Paula Peyrani, MD is an infectious disease specialist in Louisville, Kentucky. She is currently licensed to practice medicine in Kentucky. She is affiliated with UofL Health - UofL Hospital and is an Instructor at U of Louisville Sch of Med.
Education & Training
University of Louisville School of MedicineFellowship, Infectious Disease, 2009 - 2011
University of Buenos AiresClass of 1999
Certifications & Licensure
KY State Medical License 2011 - 2025
Clinical Trials
- Failure and Cardiovascular Events in Community-acquired Pneumonia Start of enrollment: 2009 Oct 01
- Patients Response to Early Switch To Oral:Osteomyelitis Study Start of enrollment: 2014 Mar 06
Publications & Presentations
PubMed
- 344 citationsSMART-COP: A Tool for Predicting the Need for Intensive Respiratory or Vasopressor Support in Community-Acquired PneumoniaPatrick G. P. Charles, Rory Wolfe, Michael Whitby, Michael J. Fine, Andrew Fuller
Clinical Infectious Diseases. 2008-08-01 - 321 citationsAdults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality.Julio A. Ramirez, Timothy L. Wiemken, Paula Peyrani, Forest W Arnold, Robert Kelley
Clinical Infectious Diseases. 2017-11-13 - 151 citationsA worldwide perspective of atypical pathogens in community-acquired pneumonia.Forest W Arnold, James T. Summersgill, Andrew S. LaJoie, Paula Peyrani, Thomas J. Marrie
American Journal of Respiratory and Critical Care Medicine. 2007-05-15
Press Mentions
- A Phase 2b/3b MenACWY-TT Study of Long-Term Antibody Persistence After Primary Vaccination and Immunogenicity and Safety of a Booster Dose in Individuals Aged 11 Through 55 YearsJune 18th, 2020
